Novo Nordisk A/S (NYSE:NVO) Shares Bought by Aviance Capital Partners LLC

Aviance Capital Partners LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 49.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,206 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. Aviance Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $1,573,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Pacific Center for Financial Services increased its stake in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. Bell Investment Advisors Inc raised its stake in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. CNB Bank acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management grew its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. raised its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Price Performance

NVO traded up $1.52 on Monday, hitting $124.57. 3,634,935 shares of the company were exchanged, compared to its average volume of 4,848,793. The business’s fifty day moving average is $127.22 and its 200 day moving average is $113.29. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm has a market capitalization of $559.01 billion, a P/E ratio of 42.96, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.